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Abstract: Doxorubicin (Dox) is one of the most important first-line drugs used in osteosarcoma 
therapy. Multiple and not fully clarified mechanisms, however, determine resistance to Dox. With 
the aim of identifying new markers associated with Dox-resistance, we found a global up-regulation 
of small nucleolar RNAs (snoRNAs) in human Dox-resistant osteosarcoma cells. We investigated if 
and how snoRNAs are linked to resistance. After RT-PCR validation of snoRNAs up-regulated in 
osteosarcoma cells with different degrees of resistance to Dox, we overexpressed them in Dox-
sensitive cells. We then evaluated Dox cytotoxicity and changes in genes relevant for osteosarcoma 
pathogenesis by PCR arrays. SNORD3A, SNORA13 and SNORA28 reduced Dox-cytotoxicity when 
over-expressed in Dox-sensitive cells. In these cells, GADD45A and MYC were up-regulated, 
TOP2A was down-regulated. The same profile was detected in cells with acquired resistance to Dox. 
GADD45A/MYC-silencing and TOP2A-over-expression counteracted the resistance to Dox induced 
by snoRNAs. We reported for the first time that snoRNAs induce resistance to Dox in human 
osteosarcoma, by modulating the expression of genes involved in DNA damaging sensing, DNA 
repair, ribosome biogenesis, and proliferation. Targeting snoRNAs or down-stream genes may open 
new treatment perspectives in chemoresistant osteosarcomas. 
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1. Introduction 
The treatment of osteosarcoma, one the most frequent tumors in childhood, relies on 
conservative surgery and neo-adjuvant or adjuvant chemotherapy, mostly based on cisplatin, 
methotrexate, and doxorubicin (Dox). In recent years, several targeted-therapies or immunotherapies 
have been evaluated in clinical trials, but these treatments did not significantly improve patients’ 
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outcome [1–3]. Chemotherapy still remains the first treatment option, although the constitutive or 
acquired resistance is a strong limitation [3]. 
Chemoresistance is mediated by decreased drug influx or increased efflux, enhanced drug 
inactivation, improved efficacy of deoxyribonucleic acid (DNA) repair machinery, prevalence of pro-
survival pathways over pro-apoptotic ones, presence of highly resistant cancer stem cells [4]. The 
main mechanism of resistance to Dox in osteosarcoma is the presence of the ATP binding cassette 
transporter B1 (ABCB1), also known as P-glycoprotein (Pgp), which effluxes Dox outside the cells 
limiting its intracellular accumulation and toxicity [5]. Pgp has been clinically validated as a robust 
biomarker predictive of patients’ outcome and response to first-line chemotherapy [6–8], but 
resistance to Dox is a multifactorial process in osteosarcoma [4]. 
Recently, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been pointed out 
as key determinants in osteosarcoma tumorigenesis, progression, invasion and drug resistance [9,10]. 
For instance, the lncRNA lung cancer associated transcript 1 (LUCAT1) sensitizes osteosarcoma cells 
to methotrexate by sponging miR-200c, a Pgp inducer [11]. Similarly, by sponging miR-645, the 
lncRNA long intergenic non-protein coding RNA 161 (LINC00161) down-regulates the pro-apoptotic 
factor interferon-induced protein with tetratricopeptide repeats 2 (IFIT-2), increasing the resistance 
to cisplatin-induced apoptosis [12]. Members of the lncRNA small nucleolar RNA host gene (SNHG) 
family have been implicated in the chemoresistance of osteosarcoma, as well. SNHG12 is higher in 
Dox-resistant osteosarcoma cells than in sensitive cells and correlates with lower patients’ survival: 
specifically, SNHG12 induces resistance by up-regulating the mir320a/myeloid cell leukemia 1 
(MCL1) axis that protects from the apoptosis induced by Dox [13]. SNHG16 favors osteosarcoma 
progression, invasion and resistance to cisplatin by sponging miR-16 and down-regulating the 
autophagy-related 4B (ATG4B) protein, impairing both cisplatin-induced autophagy and apoptosis [14]. 
If lncRNAs have been extensively studied in the progression and resistance of osteosarcoma, 
less attention has been payed to small nucleolar RNAs (snoRNAs). Structurally, snoRNAs are divided 
into two families: (i) the box H/ACA snoRNAs (SNORA), characterized by hairpins complementary 
to ribosomal RNA (rRNA), separated by the H-box region and terminated with an ACA motif; (ii) 
the box C/D snoRNAs (SNORD) that have a terminal stem and sequence motifs (termed C, C’, D’ and 
D) complementary to the target rRNA [15]. SnoRNAs have been identified as organizers of nucleolar 
RNA [16] or as guides for methylation, pseudo-uridylation and acetylation of rRNA [15]. Now, it is 
clear that snoRNAs are also exported from the nucleolus [17], mediate mRNA processing, compete 
with other ncRNAs or proteins for binding functional sites on mRNA [15,18]. In addition, they 
modulate exome recruitment and chromatin remodelling [15,18]. Some snoRNAs are included at 5′-
end of lncRNAs [16]; others–belonging to SNORD subfamily-produce regulatory RNAs, termed sno-
miRNAS [19], enlarging the number of biological processes controlled. Most snoRNAs are contained 
within introns of pre-mRNA [17]: they are transcribed by RNA polymerase II and require the activity 
of specific endo/exonucleases to mature [20]. The set of splicing and maturation enzymes is different 
in each organ [21,22], as well as in tumors [23], implying a highly variable pattern of snoRNAs in 
different tissues. In cancers, snoRNAs have either an oncogene or an onco-suppressor function: they 
have been implicated in cell proliferation, apoptosis and metastasis, as a consequence of the up- or 
down-regulation of the respective host genes [24,25]. To the best of our knowledge, linkages between 
snoRNAs and drug resistance have not been reported yet. 
Dox is a strong inducer of nucleolar stress because the DNA damage elicited by the drug 
disaggregates the nucleolar structure, impairs the ribosome biogenesis, promotes the translocation of 
the cytoprotective protein nucleophosmin from nucleolus to cytoplasm [26]. Dox exposure also 
activates a broad transcriptional program that decreases aminoacid biosynthesis, tRNA 
aminoacylation and general translation [27]. In human osteosarcoma U-2OS cells, Dox-induced DNA 
damage increases the ubiquitination of ribosomal proteins of both 40 S and 60 S subunits [28]. 
Moreover, Dox inhibits mammalian target of rapamycin (mTOR) activity: as a consequence, the 
phosphorylation of p70 S6 kinase (p70 S6K) and of the eukaryotic initiation factor 4E-binding protein 
1 (eIF4E-BP1) are reduced. These events impair the p70 S6K-mediated phosphorylation of ribosomal 
proteins and sequester the cap-binding protein eIF4E, respectively [29]. Another ribosome-related 
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mechanism of Dox cytotoxicity is the cytoplasmatic export of C/D snoRNAs contained in the introns 
of the ribosomal protein L13a (Rpl13a), a physiological contributor of cell death in response to 
oxidative stress [30]. The sum of the decreased ribosome biogenesis, increased ribosomal protein 
degradations, and lower efficiency of the initiation complex dramatically reduce protein translation 
and trigger apoptosis in Dox-sensitive cells. On the other hand, resistance to Dox has been associated 
to the increased expression of specific ribosome components. In U-2OS cells, Dox-induced DNA 
damage and cell cycle arrest decrease the expression of the nucleolar protein ribosomal RNA 
processing 12 homolog (RRP12) that is involved in the export and maturation of 40 S and 60 S 
ribosome components. By contrast, RRP12 overexpression determines Dox resistance [31]. Similarly, 
the aberrant expression of the receptor for activated C-kinase 1 (RACK1) and its ribosomal 
localization induces resistance to Dox, by phosphorylating eIF4E that triggers the preferential 
translation of pro-survival factors [32]. 
Considering the pleiotropic biological processes controlled by lncRNAs in osteosarcoma, the 
physiological role of snoRNAs as modulators of ribosomal functions and the inhibitory effects of Dox 
on ribosome biogenesis and protein translation, we explored the panorama of snoRNAs in Dox-
sensitive and Dox-resistant human osteosarcoma cells, with the goal of identifying possible cause-
effect relations between the expression of specific snoRNAs and the resistance to Dox. 
2. Results 
2.1. snoRNA Family is Up-Regulated in Doxorubicin-Resistant Osteosarcoma Cells 
Transcriptome profiling of Dox-sensitive U-2OS cells and of their resistant variants (U-
2OS/DX30, U-2OS/DX100 and U-2OS/DX580), characterized by progressively increasing resistance to 
Dox [26], was performed. Figure S1A shows the genes significantly modulated in resistant variant. 
As expected, specific genes involved in drug resistance, such as ABCB1, encoding for Pgp, were found 
up-regulated in Dox-resistant cells. Interestingly, several snoRNAs were included within the 
significantly modulated genes. 
The analysis of the 277 snoRNAs probes present in the array (Table S1) confirmed that 160 
snoRNAs were up-regulated by Dox treatment in U-2OS cells or at least in one resistant variant 
(Figure 1A). Specifically, 127, 132, 23, and 1 snoRNAs were significantly regulated (p < 0.05) by Dox-
treatment in U-2OS, U-2OS/DX30, U-2OS/DX100 and U-2OS/DX580 cells, respectively (Figure 1B). 
Furthermore, considering the comparison of the expression levels of these snoRNAs between 
resistant and sensitive cells, 139 out of the 160 Dox-regulated snoRNAs were up-regulated at least in 
one resistant variant (Figure 1C). 
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Figure 1. snoRNA family is up-regulated upon doxorubicin treatment and in doxorubicin-resistant 
osteosarcoma cells. (A) Heatmap of snoRNA expression changes upon 5 μM Dox treatment for 24 h, 
in Dox-sensitive U-2OS cells and Dox-resistant variants (U-2OS/DX30, U-2OS/DX100 and U-
2OS/DX580) (left) or computed between U-2OS cells and resistant variants (right). (B) UpSet plot 
reporting the overlap between snoRNA significantly and differentially expressed upon Dox treatment 
in sensitive and resistant cells (C) UpSet plot reporting the overlap between snoRNA upregulated in 
Dox-resistant variants compared to Dox-sensitive cells. The results are the means of two independent 
experiments. 
2.2. SNORD3A, SNORA13 and SNORA28 Are Ontologically and Functionally Related to Doxorubicin 
Resistance in Osteosarcoma Cells 
We re-validated the expression of each snoRNAand host genes of known biological meaning 
(https://www.genecards.org/) by RT-PCR in Dox-sensitive osteosarcoma cells and in the resistant 
variants. In 3 cases–SNORD3A and organic solute carrier partner 1 (OSCP1), SNORA13 and 
erythrocyte membrane protein band 4.1 like 4A (EPB41L4A), SNORA28 and eukaryotic translation 
initiation factor-5 (EIF5)–both snoRNAs and host genes were progressively up-regulated with the 
increase of Dox-resistance (Figure 2A), with a strong linear correlation between the expression level 
of snoRNA and host gene mRNAs (Figure 2B). The levels of OSCP1, EPB41L4A and EIF5 proteins 
varied accordingly to the respective mRNAs (Figure 2C). This trend was not cell line-specific: indeed 
SNORD3A, SNORA13 and SNORA28 and their respective host genes were progressively up-
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regulated also in the Dox-resistant variants Saos-2/DX30, Saos-2/DX100 and Saos-2/DX580 (Figure 
S2A,B) derived from Dox-sensitive Saos-2 cells, a second human osteosarcoma cell line [33]. These 
robust correlations led us to hypothesize that these 3 snoRNAs were processed and functioning in 
Dox-resistant variants. We thus investigated if they may play a role in determining the resistance to 
Dox of osteosarcoma cells. 
The Gene Ontology Analysis, available for SNORD3A, identified RNA processing, protein 
synthesis initiation and chromosome segregation as the biological processes more strictly controlled 
(Table S2), in line with the already known physiological role of this snoRNA [34]. Interestingly, the 
“doxorubicin DB00997 human GSE58074 sample 3180” was the “Drug perturbation” dataset most 
correlated with SNORD3A (Table S3). No association data were available for SNORA13 and 
SNORA28. 
 
Figure 2. SNORD3A, SNORA13 and SNORA28 up-regulation in doxorubicin-resistant osteosarcoma 
cells. (A) mRNA levels of SNORD3A, SNORA13 and SNORA28 and their host genes (OSCP1, 
EPB41L4A and EIF5) were evaluated by RT-PCR, in triplicates. Data are means ± SD (n = 3). * p < 0.05, 
*** p < 0.001: DX-variants vs. U-2OS cells. (B) Linear correlation between the relative expression of 
snoRNAs and the relative expression of the host genes, according to the RT-PCR results of Figure 2A. 
(C) Immunoblot of the indicated proteins. The figure is representative of one out of three experiments. 
Tubulin was used as control of equal protein loading. 
To functionally validate the role of SNORD3A, SNORA13 and SNORA28 as inducers of Dox 
resistance, we over-expressed them in Dox-sensitive U-2OS cells (Figure 3A). The expression levels 
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of ectopic snoRNAs in U-2OS cells was in the range of U-2OS/DX30 and U-2OS/DX100 variants 
(Figures 2A and 3A). Dox intracellular accumulation in snoRNA-over-expressing cells remained 
similar to parental U-2OS cells (Figure 3B). Also, the amount of Pgp in SNORD3A-, SNORA13- and 
SNORA28-expressing cells was comparable to U-2OS cells, and lower than the amount of Pgp 
detected in resistant variants (Figure 3C). However, snoRNA-over-expressing cells were more 
resistant to the cytotoxic effects of Dox. As expected, Dox significantly increased the release of lactate 
dehydrogenase (LDH) (Figure 3D), a marker of cell necrosis, and decreased cell viability (Figure 3E,F) 
in U-2OS cells, not in U-2OS/DX30 and U-2OS/DX100 variants. Interestingly, SNORD3A-, SNORA13-
and SNORA28-over-expressing cells did not show any increase in LDH release (Figure 3D) or 
decrease in cell viability (Figure 3E,F), suggesting that each snoRNA can induce resistance to Dox in 
sensitive cells. 
 
Figure 3. SNORD3A, SNORA13 and SNORA28 induce resistance to doxorubicin in sensitive 
osteosarcoma cells. U-2OS cells were transfected with empty vector (Ctrl) or expression vectors for 
SNORD3A, SNORA13 and SNORA28. When indicated, cells were treated with 5 μM Dox for 3 h (panel 
B), 24 h (panel D), 72 h (panels E,F). U-2OS/DX30, U-2OS/DX100 and U-2OS/DX580 cells were used 
as control of Dox-resistant cells. (A) mRNA levels of SNORD3A, SNORA13 and SNORA28, evaluated 
by RT-PCR, in triplicates. Data are means + SD (n = 3). *** p < 0.001: snoRNA-over-expressing U-2OS 
cells vs. Ctrl cells. (B) Intracellular doxorubicin accumulation, measured fluorometrically, in 
duplicates. Data are means ± SD (n = 3). * p < 0.05, *** p < 0.001: snoRNA-over-expressing U-2OS cells 
vs. Ctrl cells. (C) Pgp immunoblot. The figure is representative of one out of three experiments. 
Tubulin was used as control of equal protein loading. (D) Release of LDH, an index of cell necrosis, 
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measured spectrophotometrically, in duplicates. Data are means + SD (n = 3). *** p < 0.001: Dox-treated 
U-2OS cells vs. Ctrl cells; °°° p < 0.001: U-2OS/DX30, U-2OS/DX100 or snoRNA-over-expressing U-
2OS cells vs. Ctrl U-2OS cells. (E) Cell viability spectrophotometric quantification after crystal violet 
staining, used as assay of cell viability. Data are means + SD (n = 4). *** p < 0.001: Dox-treated U-2OS 
cells vs. Ctrl cells; °°° p < 0.001: U-2OS/DX30, U-2OS/DX100 or snoRNA-over-expressing U-2OS cells 
vs. Ctrl U-2OS cells. (F) Representative photographs of crystal violet staining. The photograph is 
representative of one out of four experiments, in quadruplicates. 
2.3. SNORD3A, SNORA13 and SNORA28 Contribute to Doxorubicin Resistance by Up-Regulating 
GADD45A and c-MYC, and Down-Regulating Topoisomerase 2A 
We next compared the expression of genes relevant for osteosarcoma pathogenesis and 
progression [1] (Figure S3) in U-2OS cells, either wild-type or over-expressing SNORD3A, SNORA13 
and SNORA28, and in U-2OS/DX30 and U-2OS/DX100 variants. As shown in Figure 4A, Dox-resistant 
variants and snoRNA-overexpressing Dox-sensitive cells shared the up-regulation of growth arrest 
and DNA-damage-inducible α (GADD45A), a sensor of stressing conditions that increases after DNA 
damage [35], and c-MYC, an oncogene commonly amplified or mutated in cancer that favors cell cycle 
progression [36]. By contrast, the cells had down-regulated topoisomerase 2A (TOP2A), an enzyme 
catalyzing the temporarily breaking of DNA double strands followed by their rejoining during DNA 
replication or transcriptions [37]. The gene modulation was confirmed by the changes in the protein 
expression (Figure 4B,C). 
 
Figure 4. SNORD3A, SNORA13 and SNORA28 up-regulate GADD45A and MYC, downregulate 
TOP2A. U-2OS cells were transfected with empty vector (U-2OS) or expression vectors for SNORD3A, 
SNORA13 and SNORA28. U-2OS/DX30, U-2OS/DX100 and U-2OS/DX580 cells were used as control 
of Dox-resistant cells. (A) Heatmaps of changes in the expression of genes relevant for osteosarcoma 
pathogenesis and progression, measured by PCR arrays (n = 4). Yellow circles: GADD45A hits; orange 
circles: MYC hits; blue circles: TOP2A hits. (B) Immunoblot of the indicated proteins. The figure is 
representative of one out of three experiments. Tubulin was used as control of equal protein loading. 
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(C) Immunoblot quantitation. The quantitation of the band density was performed using the ImageJ 
software. Data are means + SD (n = 3). * p < 0.05, *** p < 0.001: U-2OS/DX30, U-2OS/DX100 or snoRNA-
over-expressing U-2OS cells vs. parental U-2OS cells. 
To evaluate if the changes in GADD45A, MYC, and TOP2A levels were responsible for the 
resistance to Dox, induced by the three snoRNAs identified, we silenced GADD45A and MYC, and 
overexpressed TOP2A in U-2OS cells overexpressing SNORD3A, SNORA13, and SNORA28 (Figure 
5A). These changes did not alter the intracellular content of Dox that remained similar to U-2OS/DX30 
and U-2OS/DX100 variants (Figure S4). Of note, the silencing of GADD45A and MYC, and the over-
expression of TOP2A re-induced the toxicity of Dox in U-2OS cells expressing SNORD3A, SNORA13 
and SNORA28, as indicated by the increase of LDH release (Figure 5B) and decrease in cell viability 
(Figure 5C; Figure S5A). Also, in U-2OS/DX30 and U-2OS/DX100 cells, the same genetic 
manipulations restored the cytotoxic effect of Dox (Figure 5C; Figure S5B). These data suggest that: 
(i) SNORD3A, SNORA13 and SNORA28 induce resistance to Dox by up-regulating GADD45A and 
MYC, and/or by down-regulating TOP2A; (ii) changes in GADD45A, MYC and TOP2A determine the 
acquired resistance to Dox, observed in U-2OS/DX30 and U-2OS/DX100 variants. 
 
Figure 5. GADD45A, MYC and TOP2A are responsible for the doxorubicin resistance induced by 
SNORD3A, SNORA13 and SNORA28. U-2OS cells were transfected with an expression vector for 
SNORD3A, SNORA13 or SNORA28. When indicated, cells were transiently transfected with a non-
targeting scrambled siRNA pool (scr), with a GADD45A- or MYC-targeting siRNA 
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(siGADD45A/siMYC) pool, with an empty vector (em) or with an expression vector for TOP2A 
(overTOP2A). U-2OS/DX30 and U-2OS/DX100 cells were included as Dox-resistant cells. Cells were 
treated with 5 μM Dox for 24 h (panel B) or 72 h (panel C). (A) mRNA levels of GADD45A, MYC and 
TOP2A, evaluated by RT-PCR, in triplicates. Data are means ± SD (n = 3). ** p < 0.01, *** p < 0.001: U-
2OS/DX30, U-2OS/DX100 or snoRNA-over-expressing U-2OS cells vs. U-2OS cells; °° p < 0.01, °°° p < 
0.001: siGADD45A/siMYC vs. scr cells, overTOP2A vs. em cells. (B) Release of LDH, an index of cell 
necrosis, measured spectrophotometrically, in duplicates. Data are means ± SD (n = 3). *** p < 0.001: 
Dox-treated U-2OS cells vs. untreated (-Dox) cells. (C) Representative photographs of crystal violet 
staining, used as assay of cell viability. The photograph is representative of one out of four 
experiments, in quadruplicates. 
3. Discussion 
Until now, the expression level of Pgp is the most robust and clinically recognized factor 
predictive of response to Dox in osteosarcoma [6,8,38]. Chemoresistance, however, relies on 
pleiotropic factors in this tumor [4]. Identifying new biomarkers of Dox-resistance is a challenge still 
open. We addressed this issue by analyzing the whole-genome expression profile of human Dox-
sensitive U-2OS cells and U-2OS/DX30, U-2OS/DX100 and U-2OS/DX580 variants, characterized by 
increasing resistance to Dox, acquired after a stepwise selection in Dox-containing medium [26]. This 
process that mimics the development of resistance acquired in patients exposed to cumulative doses 
of Dox, generated two variants–U-2OS/DX30 and U-2OS/DX100–with moderate resistance to the 
drug [33,39] and levels of Pgp comparable to those observed in the majority of clinical specimens [6–8]. 
U-2OS/DX580 cells exacerbated the expression of Pgp because of the high concentration of Dox stably 
present in their culture medium and were representative of rare and strongly resistant osteosarcomas. 
In our unsupervised analysis, we found a general up-regulation of the snoRNA family as a 
typical feature of Dox-resistant variants. Interestingly, the up-regulation of single snoRNAs, as well 
as the number of snoRNAs up-regulated, was higher in U-2OS/DX30 and U-2OS/DX100 variants. 
These observations led us to hypothesize that snoRNA up-regulation may be associated with the first 
phases of acquisition of resistance, i.e., with the transition from Dox-sensitive cells, represented by 
U-2OS model, to moderately Dox-resistant cells, as U-2OS/DX30 and U-2OS/DX100 variants are. To 
validate our hypothesis, we narrowed our focus, excluding the snoRNAs with multiple chromosomal 
localizations and with unknown host genes. Indeed, since snoRNAs are contained in intronic 
sequences of multiple genes [18,20], analyzing the effects of snoRNAs localized in more than one 
chromosome is biased by the fact that multiple host genes are simultaneously modulated by one 
single snoRNA. The lack of knowledge of the host gene and the complex processing of the host 
mRNAs required to release snoRNAs [16,19,23] that can produce non-functioning snoRNAs and host 
gene mRNAs, are additional biases. In the group of snoRNAs characterized by one or two 
chromosomal localizations, and by a known host gene, only three, namely SNORD3A, SNORA13, 
and SNORA28, displayed a good correlation between their increase and the increase in the host gene 
mRNA and protein, suggesting that their processing in osteosarcoma cells was complete and 
produced functioning snoRNAs. 
SNORD3A helps the processing of rRNA and its host gene OSCP1 is a tumor suppressor gene 
[40]. Moreover, it encodes for a membrane protein involved in drug transport in placenta [41]. 
SNORA13 is contained in both the 5′-UTR/promoter region and in the anti-sense sequence of 
EPB41LA4, a protein connecting cytoskeleton and plasmamembrane, and stimulating the β-catenin 
signaling [42]. SNORA28 is within an intron of EIF5, a critical factor in the assembly of ribosomal 
initiation complex and GTP-driven peptide elongation [43]. To the best of our knowledge, no studies 
investigating the levels of SNORA13 and SNORA28, nor the effects of their overexpression or 
silencing, have been performed in osteosarcoma and in other tumor types. SNORD3A and its host 
genes OSCP1 were found down-regulated in uterine cervix cancer [44], although the biological and 
clinical meaning of this change has not been investigated. In contrast to our data, in breast cancer, 
SNORD3A overexpression chemosensitizes cells to 5-fluorouracil (5-FU), by negatively regulating 
miR-185-5p. The result is an increase of uridine monophosphate synthetase, the target enzyme of 5-
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FU [45]. We did not measure the level of endogenous miR-185-5p in osteosarcoma cells. We are aware 
that the pattern of miRNAs is highly variable between tumors: this factor must be considered since 
it may strongly impact on the biological effects of the same snoRNA in different tumor types. 
Interestingly the Gene Ontology analysis performed in the present study indicated Dox-related 
biological processes as the most strongly associated with SNORD3A. This is in line with previous 
experimental works, demonstrating that one of the mechanisms by which Dox induces cell death is 
the reduced biogenesis of ribosomes [27] and/or the increased ubiquitination of ribosomal proteins 
[28], with a consequent dramatic reduction of protein translation. On the contrary, the overexpression 
of proteins that restore the ribosomal efficiency, such as RRP12 [31] and RACK1 [32], is associated 
with Dox resistance. We thus speculated that the increase in snoRNA may be a compensatory 
response to prevent the ribosomal stress induced by Dox, leading to the acquisition of resistance. 
In order to prove this hypothesis, we over-expressed SNORD3A, SNORA13 and SNORA28 in 
Dox-sensitive U-2OS cells. By this approach we over-expressed specific snoRNAs in a controlled way. 
We excluded to silence these snoRNAs in Dox-resistant variants, because the short length of 
snoRNAs, their redundancy and high homology could produce off-target and non-specific effects. 
Our results indicated that the increase in SNORD3A, SNORA13, and SNORA28 was associated with 
the resistance to Dox cytotoxicity: indeed, snoRNA-over-expressing U-2OS cells have the same 
viability of U-2OS/DX30 and U-2OS/DX100 cells in response to Dox. This resistance was independent 
on the amount of the drug. The content of intracellular Dox is strictly regulated by the rate of its influx 
and efflux. Pgp level is the main determinant of Dox intracellular content in osteosarcoma [39]. Since 
SNORD3A, SNORA13 and SNORA28 did not increase the expression of Pgp in U-2OS cells, they did 
not change the intracellular retention of the drug that remained as high as in parental U-2OS cells 
and higher than in U-2OS/DX30 and U-2OS/DX100 variants. Therefore, we concluded that the lower 
cell death induced by Dox relies on causes independent from the intracellular drug retention. 
To identify possible factors involved in this resistance, we analyzed the expression of 88 genes 
considered relevant for osteosarcoma pathogenesis and progression [1]: we compared the profiles of 
the U-2OS/DX30 and U-2OS/DX100 variants, characterized by a “patient-like” acquisition of 
resistance to Dox, and of snoRNA-over-expressing U-2OS cells. Three genes displayed the same 
modulation in all the five variants analyzed: GADD45A and MYC that were both up-regulated, and 
TOP2A that was down-regulated. The functional involvement of these three factors in Dox-resistance 
was proved by our reverse-genetic experiments. Indeed, the silencing of GADD45A and MYC, as well 
as the over-expression of TOP2A restored the sensitivity to Dox. This event was observed not only in 
SNORD3A-, SNORA13- and SNORA28-over-expressing U-2OS cells, but also in U-2OS/DX30 and U-
2OS/DX100 variants. The results suggested that GADD45A, MYC and TOP2A may mediate the 
acquisition of resistance to Dox during cumulative exposure, as in the case of U-2OS/DX30 and U-
2OS/DX100 variants, likely acting as down-stream targets of SNORD3A, SNORA13 and SNORA28. 
The increase in the DNA-damaging sensor GADD45A is not unexpected in U-2OS/DX30 and U-
2OS/DX100 variants, which are continuously exposed to Dox, an inhibitor of topoisomerase 2 and an 
inducer of DNA strand breaks [46]. The acute increase of GADD45A is usually associated to apoptosis 
in osteosarcoma [47,48], but its prolonged increase is a compensatory response to chemotherapeutic 
drugs and is related to the acquisition of resistance to methotrexate [49]. MYC is a potent driver of 
osteosarcoma tumorigenesis [50] and its transcriptional up-regulation has been associated with 
resistance to Dox in solid cancers [51,52]. As for GADD45A, the increase of MYC is a marker of DNA 
double strand breaks and genomic instability, as well as a marker of resistance to chemotherapeutic 
drugs damaging DNA, because it transcriptionally activates several DNA repairing genes [53]. 
Moreover, MYC up-regulation increases the synthesis of rRNA and the rate of protein translation in 
colon cancer cells [54], thus counteracting the ribosomal stress induced by Dox. Consistently with 
these premises, the silencing of GADD45A and MYC chemosensitized Dox-resistant osteosarcoma 
cells, by disrupting adaptive responses functional to acquire Dox-resistance. 
The over-expression of TOP2A is strongly associated with a good therapeutic efficacy of Dox 
[55]. By contrast, the decrease in TOP2A mRNA [56], the expression of truncated and non-functioning 
forms of TOP2A [57] or the enzyme inhibition [58] are all associated with resistance to Dox. Indeed, 
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as it occurs for many chemotherapeutic drugs, mutations and/or decrease in the target make the drug 
less effective. In line with these findings, resistant osteosarcoma cells had a decreased expression of 
TOP2A, but its re-introduction restores Dox efficacy. 
We propose that the continuous exposure to Dox elicits a nucleolar stress that induces a massive 
change in snoRNA processing, release and localization [26,30]. Surviving cells, i.e., cells acquiring 
resistance to Dox, up-regulate specific snoRNAs that modulate the expression of host and down-
stream genes, functional to the cell survival notwithstanding the unfavorable conditions. This 
adaptive process leads to the progressive acquisition of resistance to Dox. The upregulation of 
SNORD3A, SNORA13 and SNORA28, and the consequent modulation of GADD45A, MYC, and 
TOP2A, are prototypical examples of this mechanism (Figure 6). 
 
Figure 6. Linkage between snoRNAs and acquisition of resistance to doxorubicin. The exposure to 
Dox induces a continuous nucleolar stress that up-regulates several snoRNAs, including SNORD3A, 
SNORA13 and SNORA28. Their increase mediates resistance to Dox by down-regulating TOP2A, the 
main target of Dox, and by up-regulating GADD45A, a DNA damaging sensor that promotes the 
adaptation to chronic stresses, and MYC, a strong oncogenic factor inducing DNA repair genes and 
ribosomal protein synthesis. Arrow: decrease or increase, respectively. 
Since the specific silencing of snoRNAs is at the moment a technical challenge, in a translational 
perspective it is more promising silencing or over-expressing the host genes. Unluckily, only in few 
cases the snoRNA host genes are known, limiting the number of druggable targets. At preclinical 
level, several siRNA- or shRNA-based tools have successfully reversed Dox resistance in 
osteosarcoma, e.g., by directly silencing Pgp [59,60] or by silencing transcription factors, as estrogen-
related receptor α (ERRα) that up-regulates Pgp [61] or nuclear factor (erythroid-derived 2)-like 2 
(NRF2) that mediates resistance to oxidative stress and up-regulates multiple ABC transporters [62]. 
The major advantage of these approaches is that they can achieve high specificity in targeting a gene 
or a pathway involved in chemoresistance. Indeed, gene therapy has been tested in phase I/phase II 
clinical trials in patients with solid and hematologic tumors refractory to standard treatments, 
obtaining satisfactory results in terms of safety and efficacy. Except four trials on Ewing’s sarcoma, 
no trials on osteosarcoma are active at the present (https://clinicaltrials.gov/). The main limitations of 
gene therapy treatments are the immunogenicity of the agents used, the presence of off-target events 
that produce undesired or toxic effects, the degradation of nucleic acids within the systemic 
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circulation or the tumor microenvironment, the presence of tumor-associated barriers that limit the 
efficient delivery of siRNA, shRNA and gene expression vectors [63]. These limitations are not 
peculiar of osteosarcoma, but common to all tumors. The use of nanoparticle-based technology is a 
promising strategy to overcome these limitations, because it allows a controlled and actively 
targeting delivery of the cargo to the tumor [64]. This approach can translate the gene therapy to the 
clinical practice in the future. 
In conclusion, we observed a surprising up-regulation of several snoRNAs in Dox-resistant 
variants of osteosarcoma cells. We found that SNORD3A, SNORA13, SNORA28 are possible 
mediators of resistance. For the first time snoRNAs were identified as mediator of resistance to Dox 
in human osteosarcoma cells and as unconventional targets to induce sensitization to Dox. Validating 
the findings obtained in this work in patient-derived samples may help to identify novel and 
unexpected biomarkers predictive of response to first-line chemotherapy. Moreover, targeting 
specific snoRNAs or their down-stream genes may open new treatment perspectives for 
chemoresistant osteosarcomas that are characterized by a high risk of relapse and poor prognosis. 
4. Materials and Methods 
4.1. Chemicals 
Fetal bovine serum (FBS) and medium for cell culture were obtained by Invitrogen Life 
Technologies (Carlsbad, CA, USA). Plasticware was purchased from Falcon (Becton Dickinson, 
Franklin Lakes, NJ, USA). The BCA kit (Sigma-Merck, St. Louis, MO, USA) was used to assess the 
protein content in all samples. Reagents for electrophoresis were from Bio-Rad Laboratories 
(Hercules, CA, USA), Dox was from Sigma-Merck. If not otherwise specified, all the other reagents 
were from Sigma-Merck. 
4.2. Cells 
Human Dox-sensitive osteosarcoma U-2OS and Saos-2 cells were obtained from ATCC 
(Manassas, VA, USA). Dox-resistant variants were established by exposing the sensitive U-2OS and 
Saos-2 cell lines to step-by-step increases in Dox concentrations. Cells were continuously cultured in 
presence of Dox during the whole selection procedure. The in vitro continuous drug exposure 
resulted in the establishment of variants, which were resistant to 30 ng/mL Dox (U-2OS/DX30 and 
Saos-2/DX30), 100 ng/mL Dox (U-2OS/DX100 and Saos-2/DX100), 580 ng/mL Dox (U-2OS/DX580 and 
Saos-2/DX580), corresponding to 1 μM Dox. Resistant variants were maintained in presence of the 
Dox concentration used for their selection [33]. Cells were grown in Iscove’s Modified Dulbecco’s 
Media (IMDM) (Invitrogen Life Technologies, Carlsbad, CA, USA) containing 10% v/v FBS, 1% v/v 
penicillin-streptomycin, 1% v/v L-glutamine. Cell lines were authenticated by microsatellite analysis 
(PowerPlex kit, Promega Corporation, Madison, WI, USA; last authentication: June 2019). 
4.3. Gene Expression Profiling Analysis 
Total RNA (300 ng) was amplified and labeled using an Illumina TotalPrep RNA Amplification 
Kit (Life Technologies, Carlsbad, CA, USA). A total of 750 ng of labeled cRNA probes was hybridized 
on the HumanHT-12 v4.0 Expression Bead Chip (Illumina, San Diego, CA, USA). Cubic spline-
normalized probe intensity data, together with detection P-values, were obtained using the 
GenomeStudio software v2011.01 (Illumina). Probes were selected only if at least one experimental 
point showed a detection p-value < 0.05. For each gene, we retained the associated probe with the 
largest mean expression value across all samples. Differential expression analysis was performed 
using the eBayes function of the LIMMA R package [65]. A gene was defined differentially expressed 
if associated with a p-value < 0.01. The association of snoRNA and target genes was obtained 
correlating their expression and selecting those with an absolute Pearson r value >0.9. The gene set 
enrichment analysis was performed using the Enrichr tools [66]. 
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4.4. SnoRNA Overexpression 
Expression vectors for SNORD3A, SNORA13 and SNORA28 were generated as follows. SnoRNA 
inserts were amplified by PCR from 100 ng of genomic DNA using PfuTurbo DNA Polymerase AD 
(Agilent Technologies, Santa Clara, CA, USA). The PCR product was cut with BamhI and XhoI 
restriction enzymes and cloned into the BamhI-XhoI sites of the pcDNA3 vector. Oligonucleotides 
are specified in Table 1 (cut sites are underlined). All vectors were sequenced before use. 
Table 1. Oligonucleotide for snoRNA expression vectors. 
Gene Primers 
SNORD3A_BAMHI_F GCGGATCCAAGACTATACTTTCAGGGATCATTTC 
SNORD3A_XHOI_R CGCTCGAGACCACTCAGACCGCGTT 
SNORA13_BAMHI_F GCGGATCCAGCCTTTGTGTTGCC 
SNORA13_XHOI_R CGCTCGAGAACTGTTACTTATGCAGCTCC 
SNORA28_BAMHI_F GCGGATCCAAGCAACACTCTGTG 
SNORA28_XHOI_R CGCTCGAGACTGTTTAAGTCTATATAACGGC 
Underlined sites: cutting sites. 
Two × 105 cells were grown until 70–80% confluence, then transfected with 1 μg of specific 
pcDNA3 plasmids using jetPRIME transfection reagent (Polyplus, New York, NY, USA), as per 
manufacturer’s instructions. SnoRNA overexpressing cells were selected with 800 mg/L G418 for 4 
days, then maintained in culture medium containing 200 mg/L G418. 
4.5. Cell Silencing/Overexpression 
Briefly, two × 105 cells were grown until 70–80% confluence. In silencing experiments, cells were 
transfected with 0.5 μg of Control non-targeting siRNA plasmid (sc-37007); GADD 45α siRNA 
plasmid (sc-35440); c-Myc siRNA plasmid (sc-29226) (all from Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA). In over-expression experiments, cells were transfected with 1 μg of Control (empty) 
CRISPR Activation Plasmid or Topo IIα CRISPR Activation Plasmid (sc-400869-ACT Santa Cruz 
Biotechnology Inc.), according to the manufacturer’s instructions. The efficacy of silencing or 
overexpression was controlled by RT-PCR (24 h after the transfection) or by immunoblot (48 h after 
the transfection). For the experiments. cells were used 48 h after the transfection. 
4.6. RT-PCR and PCR Array 
Total RNA was extracted and reverse-transcribed using iScriptTM cDNA Synthesis Kit (Bio-Rad 
Laboratories). The RT-PCR was performed with the IQ SYBR Green Supermix (Bio-Rad Laboratories). 
The primer sequences are listed in Table 2. The relative quantitation was performed by comparing 
each PCR product with the housekeeping PCR product S14, using the Bio-Rad Software Gene 
Expression Quantitation (Bio-Rad Laboratories). The PCR arrays were performed on 1 μg cDNA, 
using the Osteosarcoma PCR Array (Bio-Rad Laboratories), as per manufacturer’s instructions. 
Table 2. Primer list 
Gene Primers 
SNORD3A_F TAGAGCACCGAAAACCACGA 
SNORD3A_R CCTCTCACTCCCCAATACGG 
OSCP1_F ATCAACATACAAGCCACCCAG 
OSCP1_R ATCATGGCGAGCAAATCGTC 
SNORA13_F TTTGTGTTGCCCATTCACTTTG 
SNORA13_R ACTTATGCAGCTCCTACACCAA 
EPB41L4A_F AAGCAGCGTGCCTGGTTAC 
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EPB41L4A_R ATGCTCCCAGATGGTATTCAGC 
SNORA28_F GTCTGACACAATTTGAGCTTGCT 
SNORA28_R ATAACGGCTTGTCTCATGGGA 
EIF5_F CACCTGAGAATAGTGACAGTGGT 
EIF5_R TCATTTGGTGGTGGTGGTGG 
GADD45A_F TGCTCAGCAAAGCCCTGAGT 
GADD45A_R GCAGGCACAACACCACGTTA 
MYC_F ACCACCAGCAGCGACTCTGA 
MYC_R TCCAGCAGAAGGTGATCCAGACT 
TOP2A_F CTAGTTAATGCTGCGGACAACA 
TOP2A_R CATTTCGACCACCTGTCACTT 
S14_F CGAGGCTGATGACCTGTTCT 
S14_R GCCCTCTCCCACTCTCTCTT 
4.7. Doxorubicin Intracellular Accumulation 
The amount of intracellular Dox was detected fluorimetrically [39], using a Synergy HT 96-well 
micro-plate reader (Bio-Tek Instruments, Winooski, VT, USA). Excitation and emission wavelengths 
were 475 and 553 nm, respectively. A blank was prepared in the absence of cells in each set of 
experiments and its fluorescence was subtracted from that measured in each sample. Fluorescence 
was converted in nmoles doxorubicin/mg cell proteins using a calibration curve. 
4.8. Immunoblot 
Cell lysates were prepared by rinsing cells with 0.5 mL of lysis buffer (125 mM Tris-HCl, 750 
mM NaCl, 1% v/v NP40, 10% v/v glycerol, 50 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM Na3VO4, 
10 mg/mL leupeptin, 10 mg/mL pepstatin, 10 mg/mL aprotinin, 1 mM phenylmethylsulphonyl 
fluoride, pH 7.5). Samples were sonicated and centrifuged at 13,000× g at 4 °C for 10 min. The 
immunoblot analyses were performed on 50 μg of proteins, using the following antibodies: anti-
OSCP1 (ab244416, Abcam, Cambridge, UK; dilution 1/2000), anti-EPB41L4A (ab67551, Abcam; 
dilution 1/500), anti-EIF5 (ab228874, Abcam; dilution 1/1000), anti-ABCB1 (C219, Novus Biologicals, 
Littleton, CO; dilution 1/250), anti-GADD45A (ab180768, Abcam; dilution 1/500), anti-MYC (10828-1-
AP, Proteintech Group Inc., Rosemont, IL, USA; dilution 1/1000), anti-TOP2A (20233-1-AP, 
Proteintech Group Inc.; dilution 1/1000), followed by a peroxidase-conjugated secondary antibody. 
Anti-β-tubulin antibody (sc-5274, Santa Cruz Biotechnology Inc.; dilution 1/1000) was used as control 
of equal protein loading. The proteins were detected by enhanced chemiluminescence (Bio-Rad 
Laboratories). The relative quantitation of immunoblot was performed with the ImageJ software 
(https://imagej.nih.gov/ij/; v1.52t). The band density of untreated cells was considered as 1 arbitrary 
unit. 
4.9. LDH Release 
The release of LDH, considered an index of cell damage and necrosis, was measured as reported 
in [67]. The results were expressed as percentage of extracellular LDH versus total (intracellular plus 
extracellular) LDH. 
4.10. Cell Viability 
One × 105 cells were stained with 5% w/v crystal violet solution in 66% v/v methanol, washed and 
photographed. Quantitation of crystal violet staining was performed after solubilizing the dye and 
reading the absorbance of each well at 540 nm (HT Synergy 96-well micro-plate reader). The mean 
absorbance of untreated cells was considered 100% and the absorbance units were expressed as 
percentage of viable cells vs. untreated cells. 
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4.11. Statistical Analysis 
Results were analyzed by a one-way analysis of variance (ANOVA) and Tukey’s test, using 
GraphPad Prism software (v6.01, San Diego, CA, USA). p < 0.05 was considered significant. All data 
were expressed as means ± SD. 
Supplementary Materials: Supplementary Materials can be found at www.mdpi.com/1422-0067/21/12/4500/s1. 
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Abbreviations 
Dox doxorubicin 
ABCB1 ATP binding cassette transporter B1 
Pgp P-glycoprotein 
lncRNA long non-coding RNA 
miRNA microRNA 
LUCAT1 lung cancer associated transcript 1 
LINC00161 long intergenic non-protein coding RNA 161 
IFIT-2 interferon-induced protein with tetratricopeptide repeats 2 
SNHG small nucleolar RNA host gene 
MCL1 myeloid cell leukemia 1 
ATG4B autophagy-related 4B 
snoRNA small nucleolar RNA 
SNORA box H/ACA snoRNA 
rRNA ribosomal RNA 
SNORD box C/D snoRNA 
mTOR mammalian target of rapamycin 
p70 S6K p70 S6 kinase 
eIF4E-BP1 eukaryotic initiation factor 4E-binding protein 1 
Rp113a ribosomal protein L13a 
RRP12 ribosomal RNA processing 12 homolog 
RACK1 receptor for activated C-kinase 1 
OSCP1 organic solute carrier partner 1 
EPB41L4A erythrocyte membrane protein band 4.1 like 4A 
EIF5 eukaryotic translation initiation factor-5 
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LDH lactate dehydrogenase 
TOP2A topoisomerase 2A 
5-FU 5-fluorouracil 
ERRα estrogen-related receptor α 
NRF2 nuclear factor (erythroid-derived 2)-like 2 
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Supplementary Materials 
 
Figure S1. snoRNA family is up-regulated in doxorubicin-resistant osteosarcoma cells. Heatmap of 
wholegenome expression profile of Dox-sensitive U-2OS cells and their resistant variants (U-
2OS/DX30, U-2OS/DX100 and U-2OS/DX580), showing the genes significantly up- or down-regulated 
in resistant variants. The heatmap represents two independent experiments with similar results. 
 
 
Figure S2. SNORD3A, SNORA13 and SNORA28 up-regulation in doxorubicin-resistant 
osteosarcoma Saos-2 cells. (A) mRNA levels of SNORD3A, SNORA13 and SNORA28 and their host 
genes (OSCP1, EPB41L4A and EIF5) were evaluated by RT-PCR, in triplicates in Saos-2 cells and in 
their resistant variants (Saos-2/DX30, Saos-2/DX100, Saos-2/DX580). Data are means + SD (n = 3). * p 
< 0.05, ** p < 0.01, *** p < 0.001: DX-variants vs. U-2OS cells. (B) Linear correlation between the relative 
expression of snoRNAs and the relative expression of the host genes, according to the RT-PCR results 
of Figure 2a. 
 
Figure S3. PCR array plate scheme of relevant genes in osteosarcoma. Grey: housekeeping genes; 
blue: internal quality controls. 
 
 
Figure S4. Intracellular doxorubicin accumulation in U-2OS cells overexpressing SNORD3A, 
SNORA13, SNORA28, subjected to GADD45A/MYC silencing or TOP2A overexpression. U-2OS cells 
were transfected with an expression vector for SNORD3A, SNORA13 or SNORA28. When indicated, 
cells were transiently transfected with a non-targeting scrambled siRNA pool (scr), with a GADD45A- 
or MYC-targeting siRNA (siGADD45A/siMYC) pool, with an empty vector (em) or with an 
expression vector for TOP2A (ovTOP2A). U-2OS/DX30 and U-2OS/DX100 cells were included as 
doxorubicinresistant cells. Cells were treated with 5 μM doxorubicin for 3 h. Intracellular doxorubicin 
accumulation, measured fluorimetrically, in duplicates. Data are means + SD (n = 3). ** p < 0.01, *** p 
< 0.001: U-2OS DX30/DX100 vs. U-2OS cells. 
  
 
 
Figure S5. Viability of U-2OS cells over-expressing SNORD3A, SNORA13, SNORA28, subjected to 
GADD45A/MYC silencing or TOP2A overexpression. U-2OS cells were transfected with an 
expression vector for SNORD3A, SNORA13 or SNORA28. When indicated, cells were transiently 
transfected with a non-targeting scrambled siRNA pool (scr), with a GADD45A- or MYC-targeting 
siRNA (siGADD45A/siMYC) pool, with an empty vector (em) or with an expression vector for TOP2A 
(ovTOP2A). Cells were treated with 5 μM doxorubicin (Dox). After 72 h, cells were stained with crystal 
violet. Spectrophotometric quantitation of the crystal violet staining. Data are means + SD (n = 4). *** p < 
0.001: Dox-treated U-2OS cells vs. untreated (− Dox) cells; °°° p < 0.001: snoRNA-over-expressing U-
2OS cells or U-2OS DX30/DX100 vs. U-2OS cells (+ Dox series); ## p < 0.01, ### p < 0.001: 
siGADD45A/siMYC/overTOP2A cells vs. respective Ctrl cells (+ Dox series). 
